Alzheon has raised $160M across 1 funding round, plus 2 undated rounds. The company is valued at $1.3B.
Alzheon completed a $10 million Series A round in April 2015 and a $50 million Series D in April 2022 to fund ALZ-801 clinical trials. In August 2020 it was also awarded a $47 million grant over five years from the U.S. National Institute on Aging.
1 funding round, the latest highlighted.
Alzheon was founded in 2013, United States.
No date is disclosed for this round.
No filing has been made.
1 dated round, newest first.
Thornapple River CapitalNNational Institute on AgingHHCL CapitalLead investors for each round are in the funding timeline.
The closest biopharmaceutical peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Alzheon is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
